A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD)
| Autor: | Valery Walker, Wenhui Wei, Eric Ghorayeb, Jonathan I. Silverberg, Angela Belland, James Schnitzer, Martha Kennedy, Zhen Chen, Michael L. Andria, John White |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry Immunology Atopic dermatitis Dermatology Life Quality Index Disease medicine.disease 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Quality of life Internal medicine Severity of illness medicine Immunology and Allergy Observational study 030212 general & internal medicine Young adult Prospective cohort study business |
| Zdroj: | Annals of Allergy, Asthma & Immunology. 123:381-388.e2 |
| ISSN: | 1081-1206 |
| DOI: | 10.1016/j.anai.2019.07.008 |
| Popis: | Background Systemic therapies are commonly used for patients with uncontrolled moderate-to-severe atopic dermatitis (AD) and impaired quality of life (QoL). However, real-world treatment patterns and unmet needs of adults with moderate-to-severe AD receiving systemic therapies are poorly quantified. Objective To evaluate unmet needs in patients with moderate-to-severe AD treated with systemic therapies. Methods Adults with AD diagnosis in past 5 years and a prescription for systemic treatment or phototherapy in past 6 months were identified from the Optum Research Database. Patients completed a survey about symptoms, treatment, and QoL. Chi-squared and t tests analyzed bivariable comparisons of demographics and outcomes. Spearman's rank-order correlation analyses examined the relationship between frequency of flares and outcomes. Results Eight hundred and one participants were included (mean age, 45.2 years; 71.8% female). In the 12 months before baseline survey, 38.3% reported no remission from AD. In the month before baseline survey, 63.6% used topical corticosteroids, and 81.3% of patients experienced 1 or more flares. Patients experiencing flares reported worse Patient-Orientated Eczema Measure (POEM), Peak Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index scores (DLQI), lower treatment satisfaction, and greater work productivity loss than patients without flares (all P Conclusion Despite receiving systemic therapies, adults with moderate-to-severe AD reported disease symptoms, recurrent flares, and impaired QoL, suggesting unmet therapeutic needs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|